Journal
PHARMACEUTICALS
Volume 14, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ph14121319
Keywords
fluorine; histone deacetylase inhibitor; anticancer drugs
Categories
Funding
- University of Bayreuth Open Access Publishing Fund
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [491183248]
Ask authors/readers for more resources
The development of new anticancer drugs is essential due to the limitations of current drugs. Histone deacetylases (HDACs) have emerged as promising targets for cancer treatment. SF5-SAHA, a newly synthesized HDAC inhibitor, showed strong inhibition of tumor cell growth and potential for further development as an anticancer drug candidate.
The development of new anticancer drugs is necessary in order deal with the disease and with the drawbacks of currently applied drugs. Epigenetic dysregulations are a central hallmark of cancerogenesis and histone deacetylases (HDACs) emerged as promising anticancer targets. HDAC inhibitors are promising epigenetic anticancer drugs and new HDAC inhibitors are sought for in order to obtain potent drug candidates. The new HDAC inhibitor SF5-SAHA was synthesized and analyzed for its anticancer properties. The new compound SF5-SAHA showed strong inhibition of tumor cell growth with IC50 values similar to or lower than that of the clinically applied reference compound vorinostat/SAHA (suberoylanilide hydroxamic acid). Target specific HDAC inhibition was demonstrated by Western blot analyses. Unspecific cytotoxic effects were not observed in LDH-release measurements. Pro-apoptotic formation of reactive oxygen species (ROS) and caspase-3 activity induction in prostate carcinoma and hepatocellular carcinoma cell lines DU145 and Hep-G2 seem to be further aspects of the mode of action. Antiangiogenic activity of SF5-SAHA was observed on chorioallantoic membranes of fertilized chicken eggs (CAM assay). The presence of the pentafluorothio-substituent of SF5-SAHA increased the antiproliferative effects in both solid tumor and leukemia/lymphoma cell models when compared with its parent compound vorinostat. Based on this preliminary study, SF5-SAHA has the prerequisites to be further developed as a new HDAC inhibitory anticancer drug candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available